Share Name Share Symbol Market Type Share ISIN Share Description
Faron Pharma LSE:FARN London Ordinary Share FI4000153309 ORD NPV (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -3.50p -3.33% 101.50p 100.00p 103.00p 105.50p 101.50p 102.50p 92,297 15:31:51
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -18.7 -67.5 - 31.49

Faron Pharma Share Discussion Threads

Showing 1026 to 1050 of 1050 messages
Chat Pages: 42  41  40  39  38  37  36  35  34  33  32  31  Older
DateSubjectAuthorDiscuss
21/9/2018
13:20
Such an unexciting share at mo
sampsun
19/9/2018
22:17
I didn't think UT's meant much? Happy to be corrected though.
dan1nat1
19/9/2018
22:16
With our limited free float good news could see us flying!
dan1nat1
19/9/2018
19:55
Does anyone else feel this could have a fantastic jump on good news?
sampsun
19/9/2018
19:54
Nice UT. B1
b1tcoin
18/9/2018
22:17
Mr MM I took off mate. Lost on the last punt. Made that mistake not pressing the sell button on the day before news and then clicked on a wrong ticker when trying to run here on news day. !!! By the time I realised my mistake it was falling rapidly. Pretty sure we will not see 60p-70, as you are at the helm, steering this ship. :) Maybe running out of luck here to re-enter, but genuine gamblers can't help it sometimes. 100p been supported B1
b1tcoin
18/9/2018
12:17
B1tcoin, Any comment today, or have you gone completely?
jobber1
18/9/2018
10:05
1000 max online at 108p so a few getting involved again
dave4545
18/9/2018
09:53
Might have a mini spike on the back of that "insider trading" rns so took some at 106p
dave4545
18/9/2018
09:32
"On 17 September 2018, a person closely associated with Dr. Matti Karvonen, Chief Medical Officer of Faron, had acquired 4,414 ordinary shares in Faron at a price of 100 pence per ordinary share"
dave4545
17/9/2018
13:59
No The Japanese results are unknown ( although my view is they may be complicated and inconclusive for many of the same reasons the European pIII trial did not meet its endpoint). Regulatory hurdles are (rightly) quite high for any new drugs.I would be most surprised if the drug was approved for use in Japan when European and American regulators require further trials due to previous trials having failed. Regulators usually err on the side of caution.
jnbrw
17/9/2018
12:07
And if the Japanese p3 trial is a success due to using data from the euro p3, we can initially move to market in that region only...or do you also take from the interview that that has failed?
dan1nat1
16/9/2018
22:24
I have rewatched the interview and the guy from the co clearly states the findings from the investigations into the p III ards trial failure will be worked into and used in the setting up of the new trials of traumakine if they go ahead. Confirmation that any commercialisation of any new products (if any of the trials are ultimately successful) are AT BEST 18 months to 2 or 3 years away. They will need a new working capital fundraising round long before then. And P II and PIII trials of any drugs that emerge as candidates will also need fund raising.
jnbrw
16/9/2018
14:32
Faron has made a major update to their pipeline on their website on 13th of September 2018. There are several new diseases mentioned in the pipeline. Interestingly there is also under Traumakine a Global, ARDS trial. The same goes for D-ARDS. I don't remember these being there before, so I checked what the pipeline used to be before from Wayback machine. They have a snapshot from the pipeline from 25th of August 2017 and at that time there wasn't a Global ARDS trial.
daa1
14/9/2018
07:59
massively oversold
inv
13/9/2018
22:11
Agreed the strategy will be different now, but until the 22nd of October please don't try to mislead people into believing you know what it will be.Based on the original strategy we had a market cap around £240m, it's now around £30m some might say we have been significantly oversold based on the positive outlook of the latest interview.
dan1nat1
13/9/2018
20:21
Dan NAT - by material I meant in terms of commercialisation ( producing and selling the drug ) which was the original strategy and what the mkt was planning for. Don't mislead others and yourself the European PIII trial failure will mean another phase three trial at best.This will cost and take years, however much people want to put a positive slant on it.
jnbrw
13/9/2018
17:15
hxxp://www.proactiveinvestors./companies/stocktube/10466/faron-pharma-to-take-clevegen-cancer-candidate-into-the-clinic-this-year-10466.html add .co.uk to get the link
dan1nat1
13/9/2018
17:14
No sure we watched the same interview, as you didn't post the link for some reason? - [...] Traumakine - full update 22nd Oct, not sure what you can possibly be basing "nothing material happening soon" on? He actually seemed very positive on the future of Traumakine, and I consider 22nd Oct to be pretty soon. Clevegen looks to be a fantastic prospect, with potential to be used as more than just a cancer treatment. Funding will be needed, but certainly not before we are updated on Traumakine and hopfully re-rated back to were we should be. I suggests everybody watches the video and makes there own mind up.
dan1nat1
13/9/2018
16:59
Just watched the interview and just confirms what I thought this am. Nothing material will happen with traumakine soon, water has been muddied too much now to hope for any sort of approvals granted imo and certainly no income from this side anytime soon ( as some have claimed). Clevegen may be a good prospect but it is going to need a lot of funds and several years to get it through the layers of trials it needs before it gets to the market. I expect funds will need to be raised in the coming months as funding requirements are not advantageous when left to the last minute.
jnbrw
13/9/2018
09:26
It does look increasingly like co are pushing clevegen to the fore and sidelining traumakine or at least downplaying its importance ( without actually saying as much).I reckon traumakine will limp on with a new " strategy" with an inconclusive Japan result and clevegen will be main focus going forward. Progressing Clevegen will need another load of fundraising to get through P II and III trials ( if successful up to that point) So ultimately, fundraising/dilution on the way imo.
jnbrw
13/9/2018
08:38
only 10 million cash left, looks like vernalis, (sold for 6p)
latifs100
13/9/2018
08:38
Holding £1 will be key. I closed my trading position on open at 110, have now reopened at 102. My Isa holdings are long term and are waiting for a minimum extra zero.
dan1nat1
13/9/2018
08:12
Yep. Stop got taken. Thanks god. Only a few % losses as last average sub 110p. I do not think it will close sub 100p though. Who knows. Good luck genuine gamblers. B1
b1tcoin
13/9/2018
07:51
Quite disappointed after such a long wait to hear about traumakine strategy. No new info about the P3 trial failure, Japanese trial outcome delayed and a wait til Oct now for info on the strategy going forward?
jnbrw
Chat Pages: 42  41  40  39  38  37  36  35  34  33  32  31  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20180923 04:59:53